Expression of arachidonate platelet-type 12-lipoxygenase in human rheumatoid arthritis typeB synoviocytes  by Liagre, Bertrand et al.
FEBS 19052 FEBS Letters 414 (1997) 159-164 
Expression of arachidonate platelet-type 12-lipoxygenase in human 
rheumatoid arthritis typeB synoviocytes 
Bertrand Liagrea, Pascale Vergneb, Michel Rigauda'*, Jean L. Beneytouta 
'^Facultes de Medecine et de Pharmacie, ERS CNRS 6101, 2 Rue du Docteur Marcland, 87025 Limoges Cedex, France 
bService de Rhumatologie, CHRU de Limoges, Hopital Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges Cedex, France 
Received 2 June 1997; revised version received 7 July 1997 
Abstract In the present study, we have demonstrated platelet-
type 12-lipoxygenase (12-LOX) expression in human rheumatoid 
arthritis (RA) type B synoviocytes by reverse-transcription 
polymerase chain reaction (RT-PCR). The presence of 12-
LOX mRNA in these cells was revealed by classical RT-PCR 
analysis using platelet-type 12-LOX cDNA primers and the 
PCR fragment (246 bp) was purified, amplified and sequenced. 
By sequence analysis, this fragment was determined to be 100% 
identical to that from platelet-type 12-LOX cDNA. Immuno-
fluorescence data demonstrate that interleukin-ip (IL-1P) 
increases cellular 12-LOX protein. Other results associate 
specific inflammatory cytokines with the activity of 12-LOX in 
human RA type B synoviocytes. IL-ip increased 125-hydroxy-
5,8,10,14-eicosatetraenoic acid (12-HETE) production (4-fold) 
and we also observed an increase in 12-HETE production (2.5-
fold) after incubation of human RA type B synoviocytes with 
TNFa. In contrast to the action of IL-ip on 12-HETE synthesis, 
IL-4 and IL-6 did not enhance 12-HETE production. This is the 
first demonstration of platelet-type 12-LOX cDNA derived from 
the mRNA of cultured human RA type B synoviocytes. 
© 1997 Federation of European Biochemical Societies. 
Key words: Rheumatoid arthritis; Human synoviocyte; 
12-Lipoxygenase; Arachidonic acid; Cytokine 
1. Introduction 
Rheumatoid arthritis (RA) is an inflammatory joint disease 
characterized by progressive destruction of joint structures 
and tissues. This process is mediated by massive inflammation 
of the synovium, leading to pannus formation [1]. The cell 
populations at the site of cartilage erosion in RA have also 
been well characterized [2-A]. Thus, macrophages and fibro-
blasts, which dominate in the synovial lining, are also prom-
inent in the eroding pannus at the synovium-cartilage junc-
tion. Based on these histologic and related experimental 
observations [5], it has been proposed that, firstly, fibro-
blast-like type B cells proliferate over the surface of the car-
tilage, followed by the accumulation of large numbers of mac-
rophage-like type A cells which participate with other cells in 
the invasion of cartilage. Type B cells contain a prominent 
rough endoplasmic reticulum, few cell processes and vacuoles, 
less dense nuclear chromatin, but more developed nucleoli. 
Type B cells have the morphologic appearance of fibroblasts 
as well as the structural machinery to synthesize and secrete 
an impressive array of products, including proteoglycans, cy-
tokines, arachidonic acid metabolites, and metalloproteinases 
[6]. Infiammed synovium contributed locally to joint destruc-
tion by the secretion of proteolytic enzymes, and also at a 
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distance by the synthesis and secretion of proinflammatory 
cytokines. Accumulating evidence suggests that some of these 
cytokines play a major role in the pathophysiology of arthritic 
disease, among which interleukin-1 (IL-1) and tumor necrosis 
factor-a (TNFa) appear to be likely candidates [1,7,8]. In 
rheumatoid synovium, IL-1 and TNFa are synthesized mainly 
by infiltrating macrophages/monocytes and synovial lining 
cells. These cytokines are very potent inducers of the synthesis 
of proteolytic enzymes, such as metalloproteases and the plas-
minogen activator, which are involved in joint tissue degener-
ation [9-11]. Interleukin-6 (IL-6) is another proinflammatory 
cytokine synthesized in large quantities by both rheumatoid 
arthritic and osteoarthritic synovium [12]. This cytokine plays 
a role in the proliferation of B lymphocytes and likely poten-
tiates the action of IL-1 which induces metalloprotease syn-
thesis by RA synovial fibroblasts [13,14]. 
Lipoxygenases are lipid-peroxidating enzymes that are im-
plicated in the pathogenesis of a variety of inflammatory dis-
orders such as arthritis, psoriasis, and asthma [15]. 5-Lipox-
ygenase (5-LOX) catalyzes the oxygenation of free 
arachidonic acid to its hydroperoxy derivative, 5-hydroper-
oxy-6,8,ll,14-eicosatetraenoic acid, the first step in the bio-
synthesis of the potent inflammatory mediators leukotrienes 
[15,16]. The 12- and 15-lipoxygenases (12-LOX and 15-LOX) 
are involved in the biosynthesis of other bioactive metabolites 
from free arachidonic acid, such as lipoxins [15]. Arachido-
nate 12-LOX is an oxygenase which incorporates one mole-
cule of oxygen into arachidonic acid to produce 125-hydro-
peroxy-5,8,10,14-eicosatetraenoic acid (125-HPETE). The 
primary hydroperoxy product is reduced to 125-hydroxy 
acid (12S-HETE). On the basis of enzymological, immunolog-
ical, and molecular biological studies, two main types of 12-
LOX ('platelet-type' and 'leukocyte-type') have been charac-
terized [17], and a novel isoform of 12-LOX has been de-
scribed [18,19]. The biological role of the 12-LOX is less clear. 
12-LOX predominates in human platelets, and one potential 
role of its product, 12-HETE, is the modulation of adhesion 
receptors [20]. However, unlike cyclooxygenase (COX) and 5-
LOX, the physiological functions of 12-LOX are still under of 
investigation. 
In our work, we sought to determine if human RA type B 
synoviocytes were really able to express 12-LOX mRNA lead-
ing to the synthesis of 12-HETE. Because cytokines have been 
implicated in the cellular response seen in arthritis [21], we 
examined the effect of different cytokines produced by cells 
present in RA on 12-LOX activity. 
2. Materials and methods 
2.1. Preparation of human synovial cells 
RA synoviocytes were isolated from fresh synovial biopsies ob-
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tained from RA patients undergoing hip synovectomy. Synovia were 
minced and digested with 1.5 mg/ml collagenase-dispase, 1 mg/ml 
hyaluronidase and 0.15 mg/ml DNase I for 3-4 h at 37°C. After 
centrifugation, cells were resuspended in Dulbecco's modified Eagle's 
medium (DMEM) (Gibco BRL) supplemented with 10% fetal calf 
serum, 4.5 g/1 D-glucose, 25 mM HEPES, 100 U/ml penicillin and 
100 ug/ml streptomycin in a humidified atmosphere containing 5% 
(v/v) CO2 at 37°C. After 48 h, non-adherent cells were removed. 
Adherent cells were cultured in complete medium and, at confluence, 
cells were trypsinized and passed. Cells were used between passages 4 
and 8 when they morphologically resembled 'fibroblast-like' synovio-
cytes [22]. Cells were cultured 45-60 days prior to experimentation. 
This delay allowed the elimination of all possible interactions resulting 
from an eventual pre-operative treatment (NSAID analgesics). No 
patients were receiving corticotherapy or chemotherapy. 
2.2. Culture of human RA type B synoviocytes 
Between passages 4 and 8, cells were trypsinized. Cell count and 
viability were determined and 106 cells were plated in 25 cm2 tissue 
culture flask (Falcon, Oxnard, CA). Viability, measured by trypan 
blue dye exclusion [23] at the start and the end of culture, was always 
greater than 95%. Cells (106) from RA patients were used for indirect 
immunofluorescence study. The following monoclonal antibodies were 
used: 5B5 (anti-prolyl hydroxylase) for fibroblasts at 1:50 dilution 
(Dako, Burlingam, CA), JC/70A (anti-CD31) for endothelial cells at 
1:50 (Dako), RM052 (anti-CD 14) for macrophages at 1:50 (Immu-
notech, Marseille, France). The negative control was a mouse anti-
body of the same isotype (Immunotech). Incubations were performed 
at room temperature for 30 min. Binding of monoclonal antibodies 
was visualized using fluorescein (DTAF)-conjugated goat anti-mouse 
antibody (Immunotech) at 1:50 dilution. 
2.3. RT-PCR analysis of 12-LOX synoviocyte culture extracts and 
verification of PCR products 
Total cellular RNA from synoviocytes was isolated using a RNA 
extraction kit (RNAzol181) based on a modification of the technique 
described by Chomczynski and Sacchi [24], reverse transcribed into 
cDNA and amplified. RNA (2 itg) was added to 0.5 u.g oligodT, 
heated to 70°C for 10 min and quick-chilled on ice. The following 
components were added to the reaction mixture: 1X synthesis buffer, 
1 mM dNTP, 0.2 mM DTT and 200 U of RT for a final reaction 
volume of 20 ill. After incubation for 50 min at 42°C, the reaction was 
terminated by heating at 70°C for 15 min and quick-chilled on ice. 
Residual RNA was destroyed by the addition of 2 U RNase H for 20 
min at 37°C. An 21-base sense primer of human platelet 12-LOX 
cDNA and an antisense primer consisting of 21 bases were designed 
to specifically amplify 246 bp of 12-LOX cDNA (Table 1) [25]. Re-
verse-transcribed cDNA (10 ul) was incubated with 10 pmol of sense 
and antisense primers, 1 mM dNTP, 0.1 U Taq polymerase in 1 X 
PCR buffer at a final volume of 50 |xl. The mixture was overlaid with 
mineral oil and amplified in a thermal cycler (Crocodile II, Appli-
gene): 94°C for 1 min during 1 cycle, denaturation at 94°C for 45 
s, primer annealing at 60°C for 45 s and extension at 72°C for 1 min 
during 35 cycles with appropriate controls. PCR products were ex-
tracted and visualized by electrophoresis on a 1.2% agarose gel con-
taining ethidium bromide in Tris-acetate EDTA buffer. Human plate-
let 12-LOX product was verified by digestion with (Ban!) (Boehringer-
Mannheim) under the following conditions. 12-LOX amplification 
product (10 ul) was incubated with Ban! for 1 h at 37°C. Resulting 
fragments were visualized by electrophoresis on a 1.5% agarose gel 
and size was calculated by linear regression with two molecular weight 
ladders (Boehringer-Mannheim and Appligene). 
2.4. Cloning and sequencing 
The PCR fragment was purified from the PCR reaction using High 
Pure PCR Product Purification Kit (Boehringer-Mannheim), and li-
gated into pGEM®-T Easy Vector (3 kb) that had been previously cut 
with EcoRY with a 3'-terminal thymidine added to both ends (Prom-
ega). The high copy number pGEM®-T Easy Vector contain T7 and 
SP6 RNA Polymerase promoters flanking a multiple cloning site 
(MCS) within the a-peptide coding region of the enzyme |3-galactosi-
dase. Recombinant plasmid was transformed into competent cells (E. 
coli JM 109), isolated and purified with Wizard"* Plus Minipreps 
DNA Purification System (Promega). Recombinant plasmid was am-
plified with Quiagen/Filter, Plasmid Maxi Kit (Quiagen GmbH) and 
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plasmid insert was sequenced by PCR amplification in a final volume 
of 20 |tl using 100 ng of PCR product, 5 pmol of pUC/M13 Forward 
Primer and 9.5 |il of DyeTerminators premix according to Applied 
Biosystems protocol. Sequencing was performed at Genome Express 
(Zone Astec, Grenoble, France). 
2.5. Immunocytochemistry 
Subconfluent human RA type B synoviocytes were dislodged by 
trypsin/EDTA treatment, 105 cells were seeded onto poly-L-lysine 
coated glass coverslips in 6-well plates, and cultured in DMEM (3 
ml/well) supplemented with 10% fetal calf serum for 24 h. Following 
adherence and spreading, IL-1(5 (50 ng/ml) or vehicle (DMEM with 
10% fetal calf serum) was added to the cells and culture continued for 
an additional 20 h. For subsequent immunofluorescent labeling of 12-
LOX protein, cells were fixed and permeabilized with methanol (5 
min, —20°C) and acetone (10 s, —20°C), and non-specific Fc-binding 
sites were blocked by incubation of all coverslips with 3% (w/v) bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS) pH 7.2 for 
30 min before incubation for 4 h with rabbit polyclonal antiserum to 
purified human platelet type 12-LOX (1:100 in PBS/3% (w/v) BSA; 
Oxford Biomedical Research) or with rabbit pre-immune serum 
(1:100 in PBS/3% (w/v) BSA) as control. After washing 3X5 min 
with PBS, cells were labeled for 1 h with FITC-conjugated goat 
anti-rabbit IgG (1:100 in PBS/3% (w/v) BSA/0.02% (w/v) Evans 
blue) (Sigma), washed again 3 times with PBS, and mounted with 
immumount (Shandon). Immunofluorescence pictures were taken 
with a Nikon microscope OPTIPHOT-2 (Nikon Corporation). 
2.6. Arachidonic acid metabolism 
Exogenous [l-14C]arachidonic acid metabolism of synoviocytes was 
analyzed by reverse-phase high performance liquid chromatography 
(RP-HPLC). After trypsinization, 106 cells were pelleted and washed 
twice with PBS to eliminate culture medium. Then, cells were resus-
pended in 0.05 M phosphate buffer (pH 8.2) and pre-incubated for 
5 min at 37°C with 2 mM CaCl2 and 0.5 mM MgCl2. Exogenous [1-
14C]arachidonic acid (1 uCi, specific activity: 55 mCi/mmol, Isotop-
chim) and 0.5 ng calcium ionophore A23187 (Sigma) were added in an 
ethanolic solution that never exceeded 0.4% and had no effect on 
arachidonic acid metabolism. After 15 min at 37°C, the reaction 
was stopped by the addition of 0.5 ml methanol containing 50 ng 
prostaglandin B2 (Sigma) as internal standard. Precipitated material 
was removed by centrifugation at 600 Xg for 10 min and the pH 
adjusted to 3-4 with phosphoric acid. Samples were stored at 
-80°C until RP-HPLC analysis. To confirm the nature of 12-LOX 
product, synoviocytes were trypsinized, pelleted and washed twice 
with PBS, resuspended in 0.05 M phosphate buffer (pH 8.2) and 
pre-incubated without (control) and with 1 (J.M of indomethacin 
(IND) (Sigma) or 1 uM of nordihydroguaiaretic acid (NDGA) ( Sig-
ma) for 30 min at 37°C prior to the addition of [l-14C]arachidonic 
acid. In other experiments, the effects of various cytokines was shown. 
IL-ip, interleukin-4 (IL-4), IL-6 and TNFa were purchased from 
R&D Systems. Human RA type B synoviocytes were cultured with 
and without cytokines at 1, 10, and 50 ng/ml for 20 h prior to the 
addition of [l-14C]arachidonic acid. 
Acidified samples and synthetic standards were injected on a 5 urn 
Radial-Packs C18 cartridge (Waters-Millipore, Saint-Quentin en Yve-
lines, France) protected by a Waters C18 Guard Pack precolumn. 
Lipoxygenase metabolites were eluted at a flow rate of 2 ml-min-1 
using a tertiary methanol-acetonitrile-H20 gradient as previous-
ly described [26]. Radioactivity was detected at the exit of the col-
umn by a Flow One/Beta A500-Packard system. Metabolites of 
[l-14C]arachidonic acid were identified by comparing their retention 
times with those of synthetic standards, by coelution experiments with 
pure 12-HETE, by shift retention time studies after methylation of 
carboxylic functions and suppression of UV absorbance after catalytic 
hydrogenation [27]. Products were quantified by measuring the areas 
under the respective peaks. Each peak count was adjusted relative to 
the total radioactivity of the corresponding sample. For each incuba-
tion, the amount of every metabolite was compared with the control 
assay. 
2.7. Statistical analysis 
Statistical analysis of differences was carried out by analysis of 
variance (ANOVA). A P-value of less than 0.05 was considered to 
indicate significance. 
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Fig. 1. RT-PCR analysis of human RA type B synoviocytes platelet 
12-lipoxygenase mRNA. After reverse transcription, PCR was per-
formed for 35 cycles with appropriate controls. PCR products were 
extracted and visualized by electrophoresis on a 1.2% agarose gel 
containing ethidium bromide in Tris-acetate EDTA buffer: the 246 
bp PCR fragment (lane 4) amplified from synoviocyte mRNA was 
purified, cloned into the vector and amplified using the Quiagen Kit 
as previously described in Section 2. The fragment was determined 
to be 264 bp after appropriate restriction (EcoRI) in length (lane 5). 
Lanes 1 and 6: Molecular weight ladders. Lane 2: Positive control: 
cDNA from chloramphenicol acetyl transferase mRNA with chlor-
amphenicol acetyl transferase primers (band at 523 bp). Lane 3: 
Negative control: same cDNA as positive control with 12-LOX pri-
mers (no band). Arrow indicates the pGEM®-T Easy Vector (3 kb) 
after restriction enzyme digestion (.EcoRI). 
3. Results 
3.1. Morphological and Immunofluorescence results 
Cells were used between passages 4 and 8. Direct observa-
tion with phase-contrast microscopy demonstrated human RA 
type B synoviocytes similar to fibroblast cells. Morphological 
observations were correlated to the immunofluorescence 
study: 99% of cells were stained with 5B5 antibody. One 
percent of cells were stained with anti-CD 14 antibody. There 
was neither anti-CD31 nor control antibody staining (data not 
shown) [28]. 
3.2. RT-PCR analysis of 12-LOX synoviocyte culture extracts 
and verification of PCR products 
Total RNA isolated from human RA type B synoviocytes 
was subjected to reverse-transcription and PCR amplification 
with the primers specific for human platelet 12-LOX cDNA 
(Table 1). Subsequent agarose gel electrophoresis revealed 
PCR product and the amplified cDNA fragment (246 bp) 
was observed in the reaction of human RA type B synovio-
cytes with the primers for human platelet 12-LOX cDNA 
(Fig. 1, lane 4). The possible contamination of genomic 
DNA in RT-PCR reaction was excluded by the fact that no 
amplification of the large intron (3 kb) in the genomic DNA 
161 
was amplified by our primers. The identity of PCR product 
was verified by restriction enzyme digestion (data not shown). 
Incubation of 12-LOX amplification product with Ban\ gave 
two fragments (83 and 163 bp) corresponding to expected 
fragments. 
3.3. Expression of platelet 12-LOX in human RA type B 
synoviocytes 
The 246 bp PCR fragment amplified from synoviocytes 
mRNA was purified using High Pure PCR Product Purifica-
tion Kit, cloned into the vector (pGEM®-T Easy), amplified 
using the Quiagen Kit and sequenced as previously described 
in Section 2. The amplified fragment was determined to be 264 
bp after appropriate restriction (EcoRT) in length (Fig. 1, lane 
5) and the cDNA fragment (246 bp) was showed 100% iden-
tity to the corresponding human platelet 12-LOX cDNA. 
3.4. Immunocytochemistry detection 
Human RA type B synoviocytes were incubated with the 
anti- 12-LOX antiserum, labeled with FITC-conjugated goat 
anti-rabbit IgG and counterstained with Evans blue. Control 
incubation with pre-immune serum in place of the anti-12-
LOX antiserum gave no positive fluorescence signals (Fig. 
2A). 12-LOX protein was detectable, localized in a diffuse 
manner (Fig. 2B,C) and treatment of cells for 20 h with IL-
1(3 (50 ng/ml) resulted in an overall increase in cellular 12-
LOX protein (Fig. 2D,E). 
3.5. Arachidonic acid metabolism 
When 106 human RA type B synoviocytes were incubated 
with exogenous [l-14C]arachidonic acid as described in Sec-
tion 2, the metabolic profile shown in Fig. 3 demonstrated 
that 12-LOX activity was present in these cells. To confirm 
12-LOX activity, an extract of synoviocytes was pre-incubated 
with a potent COX inhibitor (IND) or a LOX inhibitor 
(NDGA) used at the same concentration of 1 uM. IND at 
1 uM had no significant effect (P = 0.3520) on 12-HETE pro-
duction (Table 2). At 1 uM, selectively NDGA inhibited the 
biosynthesis of 12-HETE (63%, P = 0.0009; Table 2). 
On the other hand, 106 synoviocytes were cultured for 20 h 
with various proinflammatory cytokines and screened for 12-
HETE synthesis. These cytokines were selected because of 
their relevance to RA and the doses were selected for their 
ability to induce relevant biological effects in other cell sys-
tems. After incubation of synoviocytes with IL-1(3 for 20 h, we 
observed a large increase in 12-HETE production, especially 
(4-fold, P< 0.0001) with 50 ng/ml of IL-lp (Table 2). In the 
same way, incubation of synoviocytes with TNFoc (50 ng/ml 
for 20 h) led to a 2.5-fold increase ( P < 0.0001) in 12-HETE 
production (Table 2). On the contrary, IL-4 and IL-6 at 50 
ng/ml had no significant effect (P = 0.89 and P = 0.91, respec-
tively) on 12-HETE production but, surprisingly, these cyto-
kines at lower concentrations (1 and 10 ng/ml) seemed to 
decrease 12-HETE production (Table 2). 
Table 1 
Oligonucleotides and PCR product size for human platelet 12-LOX 
cDNA species 5'-Primer Corresponding 
nucleotides 
3'-Primer Corresponding 
nucleotides 
Size of PCR 
product (bp) 
Reference 
Human platelet TCAGATTTCCAAC 
12-Lipoxygenase TGCACGAG 
1048-1068 CCGACGGAGCAA 
CTGTACATG 
1273-1293 246 [25] 
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Fig. 2. Immunofluorescence detection of 12-LOX protein in human RA type B synoviocytes. Cells were cultured for 24 h in medium containing 
10% fetal calf serum before addition of fresh medium without (A,B,C) or with IL-lp at 50 ng/ml (D,E). A: control: after 20 h, cells were fixed 
and incubated with rabbit pre-immune serum and immunofluorescent (FITC-labeled, stained with Evans blue) secondary antibody. B,C,D,E: 
after 20 h, cells were fixed and stained for 12-LOX protein using 12-LOX-specific primary and immunofluorescent (FITC-labeled, stained with 
Evans blue) secondary antibody. Immunofluorescence pictures were taken with a Nikon microscope OPTIPHOT-2 (magnification X400). 
4. Discussion 
5-LOX metabolizes arachidonic acid into leukotrienes, a 
series of potent inflammatory mediators which clearly play 
an important role in inflammatory responses [15]. The proper-
ties of 12- and 15-LOX are not clear. Although a great num-
ber of biological functions have been attributed to the metab-
olites of these enzymes, no clear roles have been demonstrated 
in physiological or pathological states [29,30]. 12-LOX exists 
in at least two isoforms which differ in substrate specificity, 
catalytic and immunological properties [31]. They are referred 
to as 'leukocyte-type' or 'platelet-type' in reference to results 
obtained with 12-LOX from porcine or bovine leukocytes or 
human or bovine platelets, respectively [31]. 
In our laboratory, Bonnet et al. [28] have shown the ex-
pression of 5-LOX and FLAP mRNAs in human cultured 
synovial cells. Moreover, these authors observed 12- and 15-
HETE production by synovial cells and suggested the pres-
ence of two other types of LOX activity, 12- and 15-LOX. On 
the other hand, in situ RT-PCR combined with immunocyto-
chemistry demonstrated that mature oligodendrocytes and as-
trocytes express 12-LOX mRNA [32]. 
In the present study, we demonstrated 12-LOX expression 
in human RA type B synoviocytes by RT-PCR analysis fol-
lowed by enzymatic digestion. The PCR fragment amplified 
from human RA type B synoviocytes mRNA was purified, 
amplified and sequenced. The cDNA fragment showed 100% 
identity to the corresponding human platelet 12-LOX cDNA. 
RT-PCR analysis in combination with cDNA sequencing the 
amplified fragment provide novel and distinct evidence for the 
presence of the platelet-type 12-LOX isoform in fibroblast-like 
synovial cells and define it as identical with human platelet 12-
LOX cDNA. 
We also demonstrated 12-LOX expression in human RA 
type B synoviocytes by RT-PCR in situ (data not shown) 
and the presence of 12-LOX protein was confirmed by immu-
nofluorescence. Moreover, our data showed that treatment of 
human RA type B synoviocytes with IL-1(3 markedly in-
creased the cellular expression of 12-LOX protein as observed 
in RIN m5F insulinoma cells [33]. 
Other results associate specific inflammatory cytokines with 
the activity of 12-LOX in human RA type B synoviocytes. In 
RA, the destruction of cartilage and bone occurs by erosion 
mainly at the junction of cartilage, bone and synovium, a 
region known as the pannus [34]. Cytokines are important 
in cartilage damage, especially IL-1 and TNFa which induce 
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Table 2 
12-HETE released from human RA type B synoviocytes with differ-
ent stimuli 
Fig. 2. (continued) 
destructive matrix metalloproteinases involved in cartilage de-
struction [11,35]; IL-1 and TNFa also induce bone resorption 
in in vitro cultures [36,37]. There is increasing evidence that 
IL-6 may inhibit bone formation and induce bone resorption 
through its stimulatory effects in osteoclasts [38]. In common 
with transforming growth factor-p (TGF-p), IL-4 also dis-
plays some immunoregulatory effects such as inhibition of 
lipopolysaccharide-induced IL-1, TNFa, PGE2, and 92-kDa 
gelatinase production in human monocytes [39]. However, in 
contrast to TGF-P, IL-4 has not been found in rheumatoid 
synovial tissue cultures [40] nor in T cells cloned from RA 
synovial biopsies [41], although it has been detected in reactive 
arthritis [42]. 
In order to eliminate the possible production of 11-HETE 
which is a COX by-product, COX and LOX inhibitors were 
used: IND (1 uM) had no effect on 12-HETE synthesis 
whereas NDGA (1 u.M) inhibited synthesis of LOX metabo-
lites. 
After demonstrating the expression of a platelet 12-LOX in 
human RA type B synoviocytes, we characterized effects of 
IL-1 (3, IL-4, IL-6 and TNFa on this enzyme activity. Our 
results showed that IL-ip increased 12-HETE production 
(4-fold) as observed in RIN m5F insulinoma cells [33] and 
in isolated pancreatic islets [43]. We also observed an increase 
in 12-HETE production (2.5-fold) after incubation of human 
RA type B synoviocytes with TNFa. This result is consistent 
with the fact TNFa is known to be the major regulator of 
Stimulus'3 Concentration" 
(12-HETE) 
Control 
IND (1 uM) 
NDGA (1 uM) 
IL-ip (1 ng/ml) 
IL-ip (10 ng/ml) 
IL-ip (50 ng/ml) 
IL-4 (1 ng/ml) 
IL-4 (10 ng/ml) 
IL-4 (50 ng/ml) 
IL-6 (1 ng/ml) 
IL-6 (10 ng/ml) 
IL-6 (50 ng/ml) 
TNFa (1 ng/ml) 
TNFa (10 ng/ml) 
TNFa (50 ng/ml) 
36.6 ± 
40.4 ± 
13.5± 
47.2 ± 
90.6 ± 
6.3 
7.6## 
4.1# 
7.0 
14.3 
152.7 ±15.8* 
13.9± 
20.9 ± 
35.7 ± 
13.1 ± 
12.4 ± 
35.9 ± 
37.4 ± 
43.2 ± 
91.3± 
3.9 
5.3 
8.1## 
2.2 
0.9 
4.9## 
3.6 
8.1 
5.2* 
^Concentration of 12-HETE is expressed as ng/106 cells. 
''Stimulus abbreviations: control, spontaneous release by unstimu-
lated human RA type B synoviocytes; IL-ip, interleukin-iP; IL-4, 
interleukin-4; IL-6, interleukin-6; TNFa, tumor necrosis factor a. 
Other abbreviations: IND, indomethacin; NDGA, nordihydroguaia-
retic acid. 
Values are expressed as mean ± SEM of three experiments (P relative 
to control group): *P<0.0001, #P = 0.0009, **P was not significant. 
IL-1 [44]. In contrast to the action of IL-ip on 12-HETE 
synthesis, IL-4 and IL-6 (50 ng/ml) did not enhance 12-
HETE production. 
In our work, we demonstrated that human RA type B 
synoviocytes are able to express platelet-type 12-LOX 
mRNA leading to the synthesis of 12-HETE which is modu-
CPM 
12-HCTE 
10 15 
nun 
Fig. 3. Extended scale of radioactive profile of human RA type B 
synoviocytes (106 cells) incubated with 1 |a,Ci [l-14C]arachidonic acid 
in the presence of calcium ionophore A23187. Arrow indicates 12-
HETE. 
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la ted by various cytokines that play a major role in the path-
ophysiology of R A especially IL-1 and TNFoc. 
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